Wockhardt (WOCKPHARMA) Q3 2026 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

• Results reviewed by Audit Committee and subjected to limited review by statutory auditors.

Financial highlights

• Standalone revenue for Q3 FY26: ₹430 crore, up from ₹325 crore in Q3 FY25; nine months revenue: ₹1,223 crore vs ₹1,047 crore YoY.

• Standalone net profit for Q3 FY26: ₹28 crore, compared to a loss of ₹22 crore in Q3 FY25; nine months net profit: ₹150 crore vs loss of ₹52 crore YoY.

• Consolidated revenue for Q3 FY26: ₹888 crore, up from ₹721 crore in Q3 FY25; nine months revenue: ₹2,408 crore vs ₹2,269 crore YoY.

• Consolidated net profit for Q3 FY26: ₹61 crore, up from ₹20 crore in Q3 FY25; nine months net profit: ₹18 crore vs ₹35 crore YoY.

• Basic EPS (consolidated) for Q3 FY26: ₹3.61; nine months: ₹2.89.

Outlook and guidance

• Group continues to monitor regulatory changes, especially regarding new Indian Labour Codes, and will adjust accounting as clarifications are issued.